Mdm2
阻害剤の選択性比較
カタログ番号 | 製品カタログ | 溶解度(25°C) | ||
---|---|---|---|---|
水 | DMSO | アルコール | ||
S2678 | NSC 207895 | <1 mg/mL | 0.4 mg/mL | <1 mg/mL |
S8059 | Nutlin-3a | <1 mg/mL | 100 mg/mL | '100 mg/mL |
S7030 | RG-7112 | <1 mg/mL | 100 mg/mL | 100 mg/mL |
S7875 | NVP-CGM097 | <1 mg/mL | 65 mg/mL | ''65 mg/mL |
S8403 | MX69 | <1 mg/mL | 95 mg/mL | 41 mg/mL |
S8606 | HDM201 (Siremadlin) | <1 mg/mL | 100 mg/mL | 3 mg/mL |
S7205 | Idasanutlin (RG-7388) | <1 mg/mL | 100 mg/mL | 8 mg/mL |
S0167 | RO8994 | <1 mg/mL | 100 mg/mL | ''13 mg/mL |
S3604 | Triptolide (PG490) | <1 mg/mL | 72 mg/mL | <1 mg/mL |
S0901 | SP141 | <1 mg/mL | 65 mg/mL | 65 mg/mL |
S2341 | (-)-Parthenolide | <1 mg/mL | 49 mg/mL | 49 mg/mL |
S1061 | Nutlin-3 | <1 mg/mL | 100 mg/mL | 30 mg/mL |
S8065 | Nutlin-3b | <1 mg/mL | 100 mg/mL | 100 mg/mL |
S7649 | MI-773 (SAR405838) | <1 mg/mL | 100 mg/mL | 31 mg/mL |
S7489 | YH239-EE | <1 mg/mL | 100 mg/mL | 18 mg/mL |
亜型選択性的な製品
Mdm2製品
製品コード | 製品説明 | 文献中Selleckの製品使用例 | お客様のフィードバック |
---|---|---|---|
S2678 |
NSC 207895NSC 207895 (XI-006) suppresses MDMX with IC50 of 2.5 μM, leading to enhanced p53 stabilization/activation and DNA damage, and also regulates MDM2, an E3 ligase. |
![]() ![]() Median overall survival of mice (n = 5 mice in vehicle and PYR-41; n = 4 mice in NSC group) inoculated with IOWA-1T xenografts were increased to 43 ± 0.5 and 39 ± 2 days with PYR-41 (PYR) and NSC-207895 (NSC), respectively, compared with a vehicle-treated control group 33 ± 1 days (*p < 0.05).
|
|
S8059 |
Nutlin-3aNutlin-3a ((-)-Nutlin-3), the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay. Nutlin-3a induces autophagy and apoptosis in a p53-dependent manner. |
![]() ![]() Nutlin-3a preserved p53 expression without influencing high glucose (HG)-induced podocyte impairment. A-D: cultured podocytes were pre-treated by nutlin-3a for 2 hrs before subjected to HG treatment. Western blotting gel documents (A) and summarized data (B) showing the expression of p53 and MDM2 in podocytes under HG exposure for 24 hrs. n = 4. Western blotting gel documents (C) and summarized data (D) showing the expression of Desmin in podocytes under HG exposure for 24 hrs. n = 3. *P < 0.05 vs. Ctrl, #P < 0.05 vs. Vehl + HG. Ctrl: control; Vehl: vehicle; nutlin-3a: nutlin-3a treatment. |
|
S7030 |
RG-7112RG7112 (RO5045337) is an orally bioavailable and selective p53-MDM2 inhibitor with HTRF IC50 of 18 nM. |
||
S7875 |
NVP-CGM097NVP-CGM097 is a highly potent and selective MDM2 inhibitor. It binds to the p53 binding-site of the Mdm2 protein, disrupting the interaction between both proteins, leading to an activation of the p53 pathway. |
![]() ![]() (C) SACi2 effects are dependent on MT-kinetochore attachments. The graph shows percentage of cells undergoing forced mitotic exit by SACi2 or DMSO in various pretreatment conditions (mean ± SEM, three independent assays). Nocodazole (Noc) was used at 70 nM and 3 μM, vinblastine (Vbl) at 1 μM, taxol (Tx) at 600 nM and monastrol (Mon) at 100 μM concentrations and were added 8 h before addition of DMSO or SACi2. MG132 (20 μM) was added 1 h before nocodazole.
|
|
S8403 |
MX69MX69 is a MDM2/XIAP inhibitor, used for cancer treatment. |
||
S8606 |
HDM201 (Siremadlin)HDM201 (Siremadlin, NVP-HDM201) is a novel, highly potent and selective inhibitor of the p53-Mdm2 interaction with affinity constant for Mdm2 in the picomolar range and a selectivity ratio greater than 10000-fold vs Mdm4. |
||
S7205 |
Idasanutlin (RG-7388)Idasanutlin (RG-7388) is a potent and selective p53-MDM2 inhibitor with IC50 of 6 nM showing improved in vitro binding as well as cellular potency/selectivity. |
||
S0167 |
RO8994RO8994 is a potent and selective small-molecule MDM2 inhibitor with IC50 values of 5 nM in HTRF binding assays and 20 nM in MTT proliferation assays, respectively. |
||
S3604 |
Triptolide (PG490)Triptolide (PG490, NSC 163062) is a diterpene triepoxide, immunosuppresive agent extracted from the Chinese herb Tripterygium wilfordii. It functions as a NF-κB inhibitor with dual actions by disruption of p65/CBP interaction and by reduction of p65 protein. Triptolide (PG490) abrogates the transactivation function of heat shock transcription factor 1 (HSF1). Triptolide inhibits MDM2 and induces apoptosis through a p53-independent pathway. |
![]() ![]() Spironolactone (sp.) and triptolide inhibit NER in myeloma cells. RPMI8226 cells were incubated with dimethyl sulfoxide (DMSO), spironolactone (10 μm) or triptolide (1 μm) for 6 h before NER evaluation. The figure represents the persistence of DNA-damage signal 150 min after exposure to UV (AFU: arbitrary fluorescent unit). Figure 4a shows representative merged pictures of DAPI and DDB2 proteo-probe signal (b).
|
|
S0901 |
SP141SP141 is a new class of MDM2 inhibitor that promotes MDM2 auto-ubiquitination and degradation, and reduces levels of MDM2 in pancreatic cancer cell lines, as well as their proliferation and ability to form tumors in nude mice. SP141 inhibits human pancreatic cancer cell growth with IC50 values of less than 0.5 μM (0.38–0.50 μM) in a p53-independent manner. |
||
S2341 |
(-)-Parthenolide(-)-Parthenolide, an inhibitor of the Nuclear Factor-κB Pathway, specifically depletes HDAC1 protein without affecting other class I/II HDACs; Also promotes the ubiquitination of MDM2 and activates p53 cellular functions. |
![]() ![]() G. To evaluate effects of IKBKE/TBK1 inhibition on NF-κB signaling in Ewing, TC32 cells were incubated with CYT387 for six hours prior to stimulation with TNF-α (30 ng/mL). IκBα degradation was measured by harvesting TC32 cells thirty minutes after stimulation with TNF-α. TNF-α stimulation resulted in degradation of IκBα, and this effect was attenuated with CYT387 treatment. Parthenolide, an inhibitor of IκBα phosphorylation was used as a positive control. Similar effects of CYT387 activity were seen in HEK-293T cells which also express IKBKΕ. Nuclear extracts were prepared from TC32 cells harvested following forty-five minutes of TNF-α stimulation. Treatment with CYT387 resulted in decreased nuclear localization of NF-κB family proteins RelA/p65 and c-Rel. There was a modest impairment of p50 nuclear localization as compared to parthenolide and DMSO controls and no change in p52 nuclear localization. RelB (not shown) is not expressed in TC32 cells |
|
S1061 |
Nutlin-3Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells. |
![]() ![]() Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.
|
|
S8065 |
Nutlin-3bNutlin-3b ((+)-Nutlin-3) is a p53/MDM2 antagonist or inhibitor with IC50 value of 13.6 μM, 150-fold less potent (+)-enantiomer of Nutlin-3 as in comparison with opposite (-)-enantiomer Nutlin-3a. |
![]() ![]() Dissociative effect of Nutlin-3a, Nutlin-3b, and RO-5963 on the preformed p53·MDM2 complex. Representative electrophoresis polyacrylamide gels in nondenaturing conditions for the analysis of the dissociation power of the inhibitors tested. (A) The reaction mixture containing 25 M p53·MDM2 complex, treated in the absence (lane 3) or in the presence (lanes 4-14) of 0.040, 0.060, 0.080, 0.12,0.33, 0.67, 1.33, 3.33, 6.67, 33.33, and 333.33 μM Nutlin-3a, respectively, were run on a 12% nondenaturing polyacrylamide gel. Thirty micromolar MDM2 and p53 was run alone in lanes 1 and 2, respectively. (B) As in (A), but using Nutlin-3b, at concentration of (lanes 4-14) of 1.33, 6.67, 13.33, 20.00, 66.67, 133.33, 266.67, 333.33, 400.00, 833.33, and 1666.67 μM. p53 and MDM2 (25 μM both) were run alone in lanes 1 and 2, respectively. (C) As in (A), but using RO-5963, at concentration of 0.10, 0.21, 0.42, 0.83, 1.67, 3.33, 8.33, 16.67, 33.33, 166.67, and 333.33 μM (lanes 4-14), respectively. (D) The percentage of the residual p53·MDM2 complex was reported in a semilogarithmic plot, at the corresponding concentration of Nutlin-3a (empty circles), RO-5963 (triangles), and Nutlin-3b (filled circles), respectively. (E) The percentage of MDM2 dissociated from the complex was reported as a function of the inhibitor concentration. Curve fitting was done using the hyperbolic function. Symbols as in (D).
|
|
S7649 |
MI-773 (SAR405838)MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1. |
![]() ![]() A panel of four NB cell lines were seeded in six-well plates with indicated concentrations of SAR405838 and agar, and grown for 2 to 3 weeks. Cells were stained with crystal violet for 4 hours. Colonies were counted and colony numbers were represented as % vehicle ± S.D. with P < 0.05 (*), P < 0.01 (**) or P < 0.001 (***) (Student's t-test, two-tailed) as indicated.
|
|
S7489 |
YH239-EEYH239-EE, the ethyl ester of YH239, is a potent p53-MDM2 antagonist and an apoptosis inducer. |
製品コード | 製品説明 | 文献中Selleckの製品使用例 | お客様のフィードバック |
---|---|---|---|
S2678 |
NSC 207895NSC 207895 (XI-006) suppresses MDMX with IC50 of 2.5 μM, leading to enhanced p53 stabilization/activation and DNA damage, and also regulates MDM2, an E3 ligase. |
![]() ![]() Median overall survival of mice (n = 5 mice in vehicle and PYR-41; n = 4 mice in NSC group) inoculated with IOWA-1T xenografts were increased to 43 ± 0.5 and 39 ± 2 days with PYR-41 (PYR) and NSC-207895 (NSC), respectively, compared with a vehicle-treated control group 33 ± 1 days (*p < 0.05).
|
|
S8059 |
Nutlin-3aNutlin-3a ((-)-Nutlin-3), the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay. Nutlin-3a induces autophagy and apoptosis in a p53-dependent manner. |
![]() ![]() Nutlin-3a preserved p53 expression without influencing high glucose (HG)-induced podocyte impairment. A-D: cultured podocytes were pre-treated by nutlin-3a for 2 hrs before subjected to HG treatment. Western blotting gel documents (A) and summarized data (B) showing the expression of p53 and MDM2 in podocytes under HG exposure for 24 hrs. n = 4. Western blotting gel documents (C) and summarized data (D) showing the expression of Desmin in podocytes under HG exposure for 24 hrs. n = 3. *P < 0.05 vs. Ctrl, #P < 0.05 vs. Vehl + HG. Ctrl: control; Vehl: vehicle; nutlin-3a: nutlin-3a treatment. |
|
S7030 |
RG-7112RG7112 (RO5045337) is an orally bioavailable and selective p53-MDM2 inhibitor with HTRF IC50 of 18 nM. |
||
S7875 |
NVP-CGM097NVP-CGM097 is a highly potent and selective MDM2 inhibitor. It binds to the p53 binding-site of the Mdm2 protein, disrupting the interaction between both proteins, leading to an activation of the p53 pathway. |
![]() ![]() (C) SACi2 effects are dependent on MT-kinetochore attachments. The graph shows percentage of cells undergoing forced mitotic exit by SACi2 or DMSO in various pretreatment conditions (mean ± SEM, three independent assays). Nocodazole (Noc) was used at 70 nM and 3 μM, vinblastine (Vbl) at 1 μM, taxol (Tx) at 600 nM and monastrol (Mon) at 100 μM concentrations and were added 8 h before addition of DMSO or SACi2. MG132 (20 μM) was added 1 h before nocodazole.
|
|
S8403 |
MX69MX69 is a MDM2/XIAP inhibitor, used for cancer treatment. |
||
S8606 |
HDM201 (Siremadlin)HDM201 (Siremadlin, NVP-HDM201) is a novel, highly potent and selective inhibitor of the p53-Mdm2 interaction with affinity constant for Mdm2 in the picomolar range and a selectivity ratio greater than 10000-fold vs Mdm4. |
||
S7205 |
Idasanutlin (RG-7388)Idasanutlin (RG-7388) is a potent and selective p53-MDM2 inhibitor with IC50 of 6 nM showing improved in vitro binding as well as cellular potency/selectivity. |
||
S0167 |
RO8994RO8994 is a potent and selective small-molecule MDM2 inhibitor with IC50 values of 5 nM in HTRF binding assays and 20 nM in MTT proliferation assays, respectively. |
||
S3604 |
Triptolide (PG490)Triptolide (PG490, NSC 163062) is a diterpene triepoxide, immunosuppresive agent extracted from the Chinese herb Tripterygium wilfordii. It functions as a NF-κB inhibitor with dual actions by disruption of p65/CBP interaction and by reduction of p65 protein. Triptolide (PG490) abrogates the transactivation function of heat shock transcription factor 1 (HSF1). Triptolide inhibits MDM2 and induces apoptosis through a p53-independent pathway. |
![]() ![]() Spironolactone (sp.) and triptolide inhibit NER in myeloma cells. RPMI8226 cells were incubated with dimethyl sulfoxide (DMSO), spironolactone (10 μm) or triptolide (1 μm) for 6 h before NER evaluation. The figure represents the persistence of DNA-damage signal 150 min after exposure to UV (AFU: arbitrary fluorescent unit). Figure 4a shows representative merged pictures of DAPI and DDB2 proteo-probe signal (b).
|
|
S0901 |
SP141SP141 is a new class of MDM2 inhibitor that promotes MDM2 auto-ubiquitination and degradation, and reduces levels of MDM2 in pancreatic cancer cell lines, as well as their proliferation and ability to form tumors in nude mice. SP141 inhibits human pancreatic cancer cell growth with IC50 values of less than 0.5 μM (0.38–0.50 μM) in a p53-independent manner. |
製品コード | 製品説明 | 文献中Selleckの製品使用例 | お客様のフィードバック |
---|---|---|---|
S2341 |
(-)-Parthenolide(-)-Parthenolide, an inhibitor of the Nuclear Factor-κB Pathway, specifically depletes HDAC1 protein without affecting other class I/II HDACs; Also promotes the ubiquitination of MDM2 and activates p53 cellular functions. |
2021, 17(11):e1009890 2020, 10(22):9923-9936 2020, 295(11):3576-3589 |
![]() ![]() G. To evaluate effects of IKBKE/TBK1 inhibition on NF-κB signaling in Ewing, TC32 cells were incubated with CYT387 for six hours prior to stimulation with TNF-α (30 ng/mL). IκBα degradation was measured by harvesting TC32 cells thirty minutes after stimulation with TNF-α. TNF-α stimulation resulted in degradation of IκBα, and this effect was attenuated with CYT387 treatment. Parthenolide, an inhibitor of IκBα phosphorylation was used as a positive control. Similar effects of CYT387 activity were seen in HEK-293T cells which also express IKBKΕ. Nuclear extracts were prepared from TC32 cells harvested following forty-five minutes of TNF-α stimulation. Treatment with CYT387 resulted in decreased nuclear localization of NF-κB family proteins RelA/p65 and c-Rel. There was a modest impairment of p50 nuclear localization as compared to parthenolide and DMSO controls and no change in p52 nuclear localization. RelB (not shown) is not expressed in TC32 cells |
製品コード | 製品説明 | 文献中Selleckの製品使用例 | お客様のフィードバック |
---|---|---|---|
S1061 |
Nutlin-3Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells. |
2022, 10.1038/s41587-021-01172-3 2022, 41(1):79 2022, 12(1):20 |
![]() ![]() Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.
|
S8065 |
Nutlin-3bNutlin-3b ((+)-Nutlin-3) is a p53/MDM2 antagonist or inhibitor with IC50 value of 13.6 μM, 150-fold less potent (+)-enantiomer of Nutlin-3 as in comparison with opposite (-)-enantiomer Nutlin-3a. |
2015, 36(24):3101-4 |
![]() ![]() Dissociative effect of Nutlin-3a, Nutlin-3b, and RO-5963 on the preformed p53·MDM2 complex. Representative electrophoresis polyacrylamide gels in nondenaturing conditions for the analysis of the dissociation power of the inhibitors tested. (A) The reaction mixture containing 25 M p53·MDM2 complex, treated in the absence (lane 3) or in the presence (lanes 4-14) of 0.040, 0.060, 0.080, 0.12,0.33, 0.67, 1.33, 3.33, 6.67, 33.33, and 333.33 μM Nutlin-3a, respectively, were run on a 12% nondenaturing polyacrylamide gel. Thirty micromolar MDM2 and p53 was run alone in lanes 1 and 2, respectively. (B) As in (A), but using Nutlin-3b, at concentration of (lanes 4-14) of 1.33, 6.67, 13.33, 20.00, 66.67, 133.33, 266.67, 333.33, 400.00, 833.33, and 1666.67 μM. p53 and MDM2 (25 μM both) were run alone in lanes 1 and 2, respectively. (C) As in (A), but using RO-5963, at concentration of 0.10, 0.21, 0.42, 0.83, 1.67, 3.33, 8.33, 16.67, 33.33, 166.67, and 333.33 μM (lanes 4-14), respectively. (D) The percentage of the residual p53·MDM2 complex was reported in a semilogarithmic plot, at the corresponding concentration of Nutlin-3a (empty circles), RO-5963 (triangles), and Nutlin-3b (filled circles), respectively. (E) The percentage of MDM2 dissociated from the complex was reported as a function of the inhibitor concentration. Curve fitting was done using the hyperbolic function. Symbols as in (D).
|
S7649 |
MI-773 (SAR405838)MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1. |
2021, 36(5):109482 2021, 5(1):96 2020, 12(8):E2157 |
![]() ![]() A panel of four NB cell lines were seeded in six-well plates with indicated concentrations of SAR405838 and agar, and grown for 2 to 3 weeks. Cells were stained with crystal violet for 4 hours. Colonies were counted and colony numbers were represented as % vehicle ± S.D. with P < 0.05 (*), P < 0.01 (**) or P < 0.001 (***) (Student's t-test, two-tailed) as indicated.
|
S7489 |
YH239-EEYH239-EE, the ethyl ester of YH239, is a potent p53-MDM2 antagonist and an apoptosis inducer. |
2018, 23(4):544-556 |